tiprankstipranks
Moderna (GB:0A45)
LSE:0A45

Moderna (0A45) Share Forecast & Price Target

11 Followers
See the Price Targets and Ratings of:

0A45 Analyst Ratings

Moderate Buy
17Ratings
9 Buy
6 Hold
2 Sell
Based on 17 analysts giving stock ratings to
Moderna
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0A45 Stock 12 Months Forecast

Average Price Target

$134.69
▲(21.63% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $134.69 with a high forecast of $310.00 and a low forecast of $61.00. The average price target represents a 21.63% change from the last price of $110.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","311":"$311","122.75":"$122.8","185.5":"$185.5","248.25":"$248.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$310.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$134.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,122.75,185.5,248.25,311],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.25,111.76923076923077,128.28846153846155,144.80769230769232,161.3269230769231,177.84615384615387,194.3653846153846,210.8846153846154,227.40384615384616,243.92307692307693,260.44230769230774,276.96153846153845,293.4807692307692,{"y":310,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.25,98.28384615384616,101.31769230769231,104.35153846153847,107.38538461538461,110.41923076923077,113.45307692307692,116.48692307692308,119.52076923076923,122.55461538461537,125.58846153846153,128.6223076923077,131.65615384615384,{"y":134.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.25,92.61538461538461,89.98076923076923,87.34615384615384,84.71153846153847,82.07692307692308,79.4423076923077,76.8076923076923,74.17307692307692,71.53846153846155,68.90384615384616,66.26923076923077,63.63461538461539,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":151.559,"date":1679616000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.205,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.694,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.274,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.467,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.125,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.15,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.84,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.75,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.32,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.1,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.25,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$310.00Average Price Target$134.69Lowest Price Target$61.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
HSBC
$86.00
Sell
-22.34%
Downside
Downgraded
02/26/24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (NASDAQ: COGT) and Moderna (NASDAQ: MRNA)
Morgan Stanley
$89.00
Hold
-19.63%
Downside
Reiterated
02/23/24
Moderna (MRNA) PT Lowered to $89 at Morgan StanleyMorgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA) to $89.00 (from $92.00) while maintaining a Equalweight rating.
Leerink Partners
$61.00
Sell
-44.91%
Downside
Reiterated
02/23/24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (NASDAQ: MRNA) and Travere Therapeutics (NASDAQ: TVTX)
Barclays
$168.00
Buy
51.71%
Upside
Reiterated
02/22/24
Moderna (MRNA) Receives a Buy from Barclays
TD Cowen
$75.00
Hold
-32.27%
Downside
Reiterated
02/22/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA) and Lantheus (NASDAQ: LNTH)

Best Analysts Covering Moderna

Which Analyst Should I Follow If I Want to Buy GB:0A45 and Sell After:
1 Month
Salveen RichterGoldman Sachs
Success Rate
16/25 ratings generated profit
64%
Average Return
+6.62%
reiterated a buy rating 5 months ago
Copying Salveen Richter's trades and holding each position for 1 Month would result in 64.00% of your transactions generating a profit, with an average return of +6.62% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Hartaj SinghOppenheimer
Success Rate
17/24 ratings generated profit
71%
Average Return
+41.50%
upgraded a buy rating 3 months ago
Copying Hartaj Singh's trades and holding each position for 3 Months would result in 70.83% of your transactions generating a profit, with an average return of +41.50% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Hartaj SinghOppenheimer
Success Rate
23/24 ratings generated profit
96%
Average Return
+280.91%
upgraded a buy rating 3 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 95.83% of your transactions generating a profit, with an average return of +280.91% per trade.
2 Years
Hartaj SinghOppenheimer
Success Rate
23/24 ratings generated profit
96%
Average Return
+505.02%
upgraded a buy rating 3 months ago
Copying Hartaj Singh's trades and holding each position for 2 Years would result in 95.83% of your transactions generating a profit, with an average return of +505.02% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A45 Analyst Recommendation Trends

Rating
Nov 23
Dec 23
Jan 24
Feb 24
Mar 24
Strong Buy
10
8
8
5
4
Buy
2
2
7
10
10
Hold
12
12
11
12
10
Sell
5
5
3
3
2
Strong Sell
0
0
1
1
1
total
29
27
30
31
27
In the current month, 0A45 has received 14 Buy Ratings, 10 Hold Ratings, and 3 Sell Ratings. 0A45 average Analyst price target in the past 3 months is $134.69.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0A45 Financial Forecast

0A45 Earnings Forecast

Next quarter’s earnings estimate for 0A45 is -$3.29 with a range of -$4.11 to -$1.94. The previous quarter’s EPS was $0.55. 0A45 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.96% of the time in the same period. In the last calendar year 0A45 has Outperformed its overall industry.
Next quarter’s earnings estimate for 0A45 is -$3.29 with a range of -$4.11 to -$1.94. The previous quarter’s EPS was $0.55. 0A45 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.96% of the time in the same period. In the last calendar year 0A45 has Outperformed its overall industry.

0A45 Sales Forecast

Next quarter’s sales forecast for 0A45 is $338.28M with a range of $0.00 to $1.18B. The previous quarter’s sales results were $2.81B. 0A45 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0A45 has Outperformed its overall industry.
Next quarter’s sales forecast for 0A45 is $338.28M with a range of $0.00 to $1.18B. The previous quarter’s sales results were $2.81B. 0A45 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0A45 has Outperformed its overall industry.

0A45 Stock Forecast FAQ

What is GB:0A45’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is $134.69.
    What is GB:0A45’s upside potential, based on the analysts’ average price target?
    Moderna has 21.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Moderna a Buy, Sell or Hold?
          Moderna has a conensus rating of Moderate Buy, which is based on 9 buy ratings, 6 hold ratings and 2 sell ratings.
            What is Moderna’s share price target?
            The average share price target for Moderna is $134.69. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $310.00 ,and the lowest forecast is $61.00. The average share price target represents 21.63% Increase from the current price of $110.737.
              What do analysts say about Moderna?
              Moderna’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Moderna?
                To buy shares of GB:0A45, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis